FDA ad comm favors Zevra’s Niemann-Pick drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: Business
Moderna is still in a Covid hangover
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: UnitedHealth and HCA clash over hospital chain’s rates in ‘battle of the giants’
Contract disputes between hospitals and health plans have become routine, but they tend to be…
STAT+: Private equity firms to acquire health care billing and payments firm R1 in $8.9 billion deal
R1 RCM is finally getting taken off the public markets, ending a months-long saga between…
STAT+: On Andrew Left and the government’s fraud case
I love the Summer Olympics. Every four years I transform into a huge fan of…
venBio raises $528 million for its fifth fund
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The debate over how long to use Alzheimer’s drugs
Good morning. We have a new investigation out today about how Mount Sinai in New…
STAT+: Wells Fargo faces class action lawsuit over workers’ high drug costs
Former employees sued Wells Fargo on Tuesday, alleging the banking giant violated federal law by…
Testing GLP-1s in Alzheimer’s, and is Medicare a good negotiator?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How to tell if Biden drove a hard bargain on drug prices
WASHINGTON — The deadline for announcing how much Medicare lowered drug prices in the first…
STAT+: For-profit hospitals are getting a boost from a flood of patients
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money…
The biotech news you need from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Leveraging scientific excellence to improve investment decisions
To invest is to embrace an unpredictable future, filled with risks and uncertainties. To navigate…
The worst for Dexcom may not be over
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Powerful Senate committee demands testimony from CEO of bankrupt Steward hospital chain
Federal lawmakers investigating the Steward Health Care bankruptcy moved on Thursday to compel testimony from…
STAT+: A preview of Neurocrine’s muscarinic drug readout
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
A potential rival for Wegovy and Zepbound enters the fray
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How UnitedHealth harnesses its physician empire to squeeze profits out of patients
UnitedHealth Group started out as a small, Minnesota health insurance company and has since morphed…
Watch: How insurers use doctors to profit off medical codes
Insurers like UnitedHealth are profiting off of the Medicare Advantage system, and it’s causing problems…
Merck lays off workers amid rough pharma job market
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Contradictory coverage decisions in North Carolina
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Four health care and biotech updates to stay on top of this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Express Scripts overcharged postal workers by $45 million, audit says
Express Scripts, one of the largest pharmacy benefit managers in the country, overcharged U.S. Postal…
Novo, Lilly shares sink due to concerns over competition
Hellloooooo. Today, we discuss the FDA’s lack of engagement with critics of MDMA for PTSD…
STAT+: Novartis not ready to admit a $3 billion mistake
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
The biotech news stories you need to know today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Elevance tumbles as health insurer warns Medicaid members are using more care
Wall Street’s reaction was swift Wednesday after Elevance Health said that the amount of care…
It’s happy hour (for now) for Alnylam
Good morning and happy Wednesday. Today we’re talking about insulin, pharma’s ties with politicians, and…
STAT+: UnitedHealth CEO concedes company was ‘over-optimistic’ about Change cyberattack recovery
UnitedHealth Group’s CEO said Tuesday that his team was “over-optimistic” about the pace at which…
Roche looks to have a competitive GLP-1 drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Medicare pay proposals are good news for health tech, bad news for docs
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
What are the odds we get an heir to Paxlovid?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: The effort to reform physician pay is set to pit primary care docs against highly paid specialists
WASHINGTON — There’s been a long lull in fighting between primary care and specialty doctors…
Element Biosciences raises another massive round
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Medicare proposes to cover some digital therapies in a breakthrough for health tech firms
In what could prove to be a lifeline for a new crop of health tech…
Can you get satiety with GLP-1s without the nausea?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biden administration ignores calls to bolster hospital price transparency
The federal government will not modify regulations that dictate how hospitals publish their prices for…
STAT+: Sanford Health aims to shake off a run of failed deals by snapping up a $3 billion Wisconsin health system
Fourth time’s the charm? Sanford Health is hoping so. Less than a year after scrapping…
uniQure shares soar on Huntington’s data
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Lilly’s obesity drug looks more potent than Novo’s in observational study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
The biotech news you missed this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: New Medicare Advantage star ratings give extra bonuses to multiple insurers
More than two dozen Medicare Advantage insurers received higher quality marks for 2024, based on…
STAT+: Former Mass General president Peter Slavin will run Cedars-Sinai in Los Angeles
Peter Slavin, who ran Massachusetts General Hospital in Boston for nearly two decades before stepping…
STAT+: Steward Health Care spent millions on surveillance of its critics — even amid financial crisis
This story was reported by Hanna Krueger, Jessica Bartlett, Mark Arsenault, and Elizabeth Koh. It was written by Krueger…
STAT+: Ascension is racing to unload hospitals as execs work to stem losses
For 15 years, a formidable CEO-CFO duo often called “the two Tonys” ushered their St….
Supreme Court undercuts regulators’ authority across government
Federal agencies’ longtime authority to regulate industries was significantly weakened by a Supreme Court decision…
Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Walgreens could shutter hundreds of underperforming stores
Walgreens is finalizing a plan to fix its U.S. business that could result in closing…
Key health care topics to watch out for at the Biden-Trump debate
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Exclusive: European VC Forbion hires Dyne CEO, expands into US
Want to stay on top of the science and politics driving biotech today? Sign up to get…